Lung Cancer News

Although use of limited resection or stereotactic body radiation therapy for early-stage non-small cell lung cancer had comparable odds for at least one adverse event, the overall toxicity profiles differed, according to study results.

It’s not often that a 2 a.m. phone call marks the highlight of someone’s career.

The FDA announced several regulatory actions the past few weeks.

Response rates to investigational therapies evaluated in NCI-sponsored phase 1 trials for solid cancers have doubled over the past 2 decades, according to study results published in The Lancet.

Linda H. Malkas, PhD, remembers the day a photograph for a newspaper changed her life.

Most patients with cancer diagnosed with myocarditis after receiving immune checkpoint inhibitors showed evidence of liver dysfunction and muscle degradation, results of an observational cohort study in JACC CardioOncology showed.

As precision medicine and tumor genomic testing play increasingly important roles in cancer treatment, the challenge of matching patients with appropriate cancer clinical trials has become more daunting.

Most oncology practices deployed immunotherapies as part of their clinical care strategy within 2 years of FDA approval for cancer indications, results of a study in JAMA Oncology showed.

The addition of tumor treating fields to standard therapies significantly improved OS for certain patients with non-small cell lung cancer, according to the therapy’s manufacturer.

Cancer drugs that received approval based on increased OS compared with other measures had the lowest median annual cost, according to a research letter published in JAMA Internal Medicine.